Powder: -20°C for 3 years | In solvent: -80°C for 1 year
ACT-281959, a prodrug of ACT-246475, is a novel potent and selective P2Y12 Receptor Antagonist with a Wider Therapeutic Window in the Rat Than Clopidogrel. ACT-281959 showed antithrombotic efficacy after oral administration in the rat ferric chloride model. ACT-281959 entered clinical studies in healthy volunteers.
Pack Size | Availability | Price/USD | Quantity |
---|---|---|---|
25 mg | 10-14 weeks | $ 2,270.00 | |
50 mg | 10-14 weeks | $ 2,980.00 | |
100 mg | 10-14 weeks | $ 4,000.00 |
Description | ACT-281959, a prodrug of ACT-246475, is a novel potent and selective P2Y12 Receptor Antagonist with a Wider Therapeutic Window in the Rat Than Clopidogrel. ACT-281959 showed antithrombotic efficacy after oral administration in the rat ferric chloride model. ACT-281959 entered clinical studies in healthy volunteers. |
Molecular Weight | 850.85 |
Formula | C38H55N6O14P |
CAS No. | 1159501-31-1 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
You can also refer to dose conversion for different animals. More
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
ACT-281959 1159501-31-1 CPD 7 HCl CPD-7 hydrochloride CPD-7 HCl CPD 7 hydrochloride CPD7 hydrochloride ACT281959 ACT 281959 inhibitor inhibit